Evidence map›Paper›PMID 30248940›Full record

ArticleInternational journal of molecular sciences2018

Melatonin Can Strengthen the Effect of Retinoic Acid in HL-60 Cells.

Olga Krestinina, Roman Fadeev, Alexey Lomovsky, Yulia Baburina, Margarita Kobyakova, Vladimir Akatov

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Melatonin as a Potential Multitherapeutic Agent.Journal of personalized medicine · 2021
    Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Olga KrestininaInstitute of Theoretical and Experimental Biophysics, Russian Academy of Science, Institutskaya St, 3, 142290 Pushchino, Moscow region, Russia. ovkres@mail.ru.
Roman FadeevInstitute of Theoretical and Experimental Biophysics, Russian Academy of Science, Institutskaya St, 3, 142290 Pushchino, Moscow region, Russia. fadeevrs@gmail.com.
Alexey LomovskyInstitute of Theoretical and Experimental Biophysics, Russian Academy of Science, Institutskaya St, 3, 142290 Pushchino, Moscow region, Russia. lomovskyalex@gmail.com.
Yulia BaburinaInstitute of Theoretical and Experimental Biophysics, Russian Academy of Science, Institutskaya St, 3, 142290 Pushchino, Moscow region, Russia. byul@rambler.ru.
Margarita KobyakovaInstitute of Theoretical and Experimental Biophysics, Russian Academy of Science, Institutskaya St, 3, 142290 Pushchino, Moscow region, Russia. ritaaaaa49@gmail.com.
Vladimir AkatovInstitute of Theoretical and Experimental Biophysics, Russian Academy of Science, Institutskaya St, 3, 142290 Pushchino, Moscow region, Russia. akatov.vladimir@gmail.com.
Institute of Theoretical and Experimental Biophysics · RUPushchino State Institute of Natural Sciences · RU

Funding

Russian Federation Government N14.Z50.31.0028Russian Foundation for Basic Research 17-04-00747
6 · The paper itself

Abstract

Melatonin is produced by the pineal gland. It can be regarded as an anticancer agent and used for combined therapy, owing to its oncostatic, antioxidant, and immunoregulatory activities. Retinoic acid is widely used for the treatment of acute promyelocytic leukemia; however, it has adverse effects on the human organism. We investigated the effect of melatonin and reduced concentrations of retinoic acid on the activation of proliferation in acute promyelocytic leukemiaon a cell model HL-60. The combined effect of these compounds leads to a reduction in the number of cells by 70% and the index of mitotic activity by 64%. Combined treatment with melatonin and retinoic acid decreased the expression of the Bcl-2. The mitochondrial isoform VDAC1 can be a target in the treatment of different tumors. The combined effect of and retinoic acid at a low concentration (10 nM) decreased VDAC1 expression. Melatonin in combination with retinoic acid produced a similar effect on the expression of the translocator protein. The coprecipitation of VDAC with 2',3'-cyclonucleotide-3'-phosphodiesterase implies a possible role of its in cancer development. The combined effect of retinoic acid and melatonin decreased the activity of the electron transport chain complexes. The changes in the activation of proliferation in HL-60 cells, the mitotic index, and Bcl-2 expression under combined effect of retinoic acid (10 nM) with melatonin (1 mM) are similar to changes that are induced by 1 μM retinoic acid. Our results suggest that MEL is able to improve the action the other chemotherapeutic agent.

Indexed as

Apoptosisbcl-X ProteinCell ProliferationCell SurvivalHL-60 CellsHumansLeukemia, Promyelocytic, AcuteMelatoninProto-Oncogene Proteins c-bcl-2TretinoinVoltage-Dependent Anion Channel 1BCL2L1 protein, humanBCL2 protein, humanbcl-X ProteinMelatoninProto-Oncogene Proteins c-bcl-2TretinoinVoltage-Dependent Anion Channel 12′,3′-cyclonucleotide-3′-phosphodiesteraseacute promyelocytic leukemiaapoptosisHL-60 cellsmelatoninretinoic acidtranslocator proteinvoltage dependent anion channel-1

Identifiers

PMID30248940
PMCPMC6213950
OpenAlexW2889932770

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.